Skip to main content

System status

Coverage is stale.

Collection is paused. Latest public event: Aug 21, 2026 (11 days ago).

← Intel index

This coverage is stale.

Last updated May 14, 2026 (about 4 months ago).

capital · May 14, 2026

Hims & Hers Launches FDA-Approved Weight Loss Medications Including Zepbound in March 2026

Share the canonical public link.

Share as image

Hims & Hers Health initiated prescriptions for Eli Lilly's Zepbound and Novo Nordisk's Wegovy on its telehealth platform starting March 2026, contributing to 125,000 Wegovy shipments in six weeks. The company reported Q1 2026 revenue of $626 million, up 46% year-over-year, but adjusted EBITDA fell to $44 million from $100 million in Q1 2025 due to 300 basis points in marketing investments and technology talent hires. CEO Andrew Dudum highlighted the shift to branded pharmaceuticals as driving subscriber growth beyond compounded semaglutide. Hims & Hers expanded its AI team to nearly 40 members, including PhDs from MIT and Berkeley, to support new specialties each targeting $100 million annual revenue.

Unable to access non-serverless model deepseek-ai/DeepSeek-V3. Please visit https://api.together.ai/models/deepseek-ai/DeepSeek-V3 to create and start a new dedicated endpoint for the model.

Supporting evidence